Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Maternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir

Combination antiretroviral therapy (cART) is successfully used for prevention of perinatal HIV transmission. To investigate safety, we compared adverse events (AE) among infants exposed to different maternal cART regimens. We reviewed 158 HIV-uninfected infants born between 1997 and 2009, using logi...

Full description

Bibliographic Details
Main Authors:	Christiana Smith, Adriana Weinberg, Jeri E. Forster, Myron J. Levin, Jill Davies, Jennifer Pappas, Kay Kinzie, Emily Barr, Suzanne Paul, Elizabeth J. McFarland
Format:	Article
Language:	English
Published:	Hindawi Limited 2016-01-01
Series:	Infectious Diseases in Obstetrics and Gynecology
Online Access:	http://dx.doi.org/10.1155/2016/9848041

Similar Items

Dyslipidaemia associated with the highly active antiretroviral therapy in aids patient: reversion after switching (stavudine to tenofovir and lopinavir/ritonavir to atazanavir/ritonavir)
by: Hamilton Domingos, et al.

Serious adverse events are uncommon with combination neonatal antiretroviral prophylaxis: a retrospective case review.
by: Christiana Smith, et al.
Published: (2015-01-01)

Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
by: Emanuela Foglia, et al.
Published: (2013-01-01)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World
by: Emanuela Foglia, et al.
Published: (2014-01-01)

Correction: Cost-Utility Analysis of Lopinavir/Ritonavir versus Atazanavir + Ritonavir Administered as First-Line Therapy for the Treatment of HIV Infection in Italy: From Randomised Trial to Real World.
by: Emanuela Foglia, et al.
Published: (2014-01-01)

Liver Profile of Atazanavir/Ritonavir in Pregnant Albino Rats
by: Elias Adikwu, et al.
Published: (2019-10-01)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
by: Eva Agnes Odongpiny Laker, et al.
Published: (2019-03-01)

Recurrent oedema associated with the co-formulation of lopinavir and ritonavir Edema recorrente associado à co-formulação de lopinavir e ritonavir
by: Jorge Francisco C. Pinto, et al.
Published: (2004-08-01)

Toxicity for warfarine switching from lopinavir/ritonavir to dolutegravir
by: Ana Pelufo-Pellicer, et al.
Published: (2017-03-01)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
by: Farinotti Robert, et al.
Published: (2010-05-01)

Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
by: Takeshi Nishijima, et al.
Published: (2013-01-01)

Safety of atazanavir/ritonavir with tenofovir disoproxil fumarate in HIV-infected adolescents
by: T. Bunupuradah, et al.
Published: (2014-04-01)

Safety and Tolerability of Antiretrovirals during Pregnancy
by: Adriana Weinberg, et al.
Published: (2011-01-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01)

Lopinavir/ritonavir for COVID-19: A living systematic review
by: Francisca Verdugo-Paiva, et al.
Published: (2020-07-01)

Cardio-metabolic effectsof HIV protease inhibitors (lopinavir/ritonavir).
by: Kathleen M S E Reyskens, et al.
Published: (2013-01-01)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
by: Ashish Chandwani, et al.
Published: (2008-09-01)

Stavudine-induced pancreatitis followed by lopinavir-ritonavir-induced pancreatitis
by: Anand H, et al.
Published: (2008-01-01)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
by: Paula Mazan, et al.
Published: (2020-05-01)

355 Lopinavir/ritonavir treatment in paediatric patients with covid-19
by: P Ip, et al.
Published: (2021-04-01)

COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Şule Özdemir, et al.
Published: (2020-12-01)

Development and Validation of Atazanavir and Ritonavir Determination in Human Plasma by HPLC-MS Method
by: T. N. Komarov, et al.
Published: (2020-02-01)

Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
by: Yohei Hamada, et al.
Published: (2013-01-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

Efavirenz and Lopinavir/Ritonavir Alter Cell Cycle Regulation in Lung Cancer
by: Rahaba Marima, et al.
Published: (2020-08-01)

Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01)

Correction: Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir).
by: Kathleen M. S. E. Reyskens, et al.
Published: (2013-01-01)

HPTLC Method for Simultaneous Determination of Lopinavir and Ritonavir in Capsule Dosage Form
by: A. V. Sulebhavikar, et al.
Published: (2008-01-01)

Novel strategies in the use of lopinavir/ritonavir for the treatment of HIV infection in children
by: Beatriz Larru Martinez, et al.
Published: (2010-03-01)

Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
by: Wilhelm P. Greffrath, et al.
Published: (2018-06-01)

The maladaptive effects of HIV protease inhibitors (Lopinavir/Ritonavir) on the rat heart.
by: Reyskens, Kathleen Maria Simone Elise
Published: (2013)

Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis
by: Bahman Amani, et al.
Published: (2021-05-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, M.D., et al.
Published: (2011-05-01)

Three Novel COVID-19 Pneumonia Cases Successfully Treated With Lopinavir/Ritonavir
by: Tatsuhiko Wada, et al.
Published: (2020-05-01)

Data on compounding lopinavir and ritonavir suspension for non-cooperative COVID-19 patients
by: D. Zanon, et al.
Published: (2020-12-01)

Lopinavir/ritonavir dosing during pregnancy in Brazil and maternal/infant laboratory abnormalities
by: Mario Ferreira Peixoto, et al.

USE OF LOPINAVIR/RITONAVIR ASSOCIATED WITH ERGOTAMINE RESULTING IN FOOT AMPUTATION: BRIEF COMMUNICATION
by: Fernando Raphael de Almeida Ferry, et al.
Published: (2014-06-01)

Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment
by: Paola Magro, et al.
Published: (2021-03-01)

Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients.
by: Nicola Gianotti, et al.
Published: (2017-01-01)